United States Digital Biomarkers in Oncology Clinical Trails Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Digital Biomarkers in Oncology Clinical Trails Market is forecast to reach at a high CAGR during the forecast period (2024-2031)

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/digital-biomarkers-in-oncology-clinical-trails-market?sb

Key Development:

United States: Digital Biomarkers in Oncology Clinical Trials

✅ In December 2025, U.S.-based oncology trials increasingly adopted wearable-derived digital biomarkers to monitor fatigue, mobility, and treatment response in real time. These tools enabled continuous patient data capture beyond hospital visits. The approach improved endpoint sensitivity and patient engagement in late-stage cancer trials.

✅ In November 2025, several FDA-supported oncology studies expanded the use of AI-driven digital biomarkers for early toxicity detection and response assessment. Remote symptom tracking and sensor-based monitoring were integrated into trial protocols. This reduced trial dropouts and enhanced safety monitoring.

✅ In October 2025, oncology sponsors in the U.S. incorporated digital biomarkers into decentralized and hybrid clinical trial models. Smartphone-based assessments and ePROs were used to track functional outcomes and quality of life. This shift accelerated recruitment and improved real-world data collection.

✅ In October 2025, collaborative oncology research programs emphasized validation of digital biomarkers as secondary and exploratory endpoints. Advanced analytics were applied to longitudinal patient data streams. These developments strengthened regulatory confidence in digital measurements for cancer trials.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=digital-biomarkers-in-oncology-clinical-trails-market

Japan: Digital Biomarkers in Oncology Clinical Trials

✅ In December 2025, Japanese oncology research centers expanded the clinical use of mobile health applications to collect digital symptom and activity biomarkers. These tools supported continuous monitoring during chemotherapy and immunotherapy trials. The data enhanced patient-centric trial designs.

✅ In November 2025, Japan-based oncology trials increasingly leveraged AI-enabled digital pathology as a source of quantitative digital biomarkers. High-resolution imaging data improved tumor characterization and response evaluation. This supported more precise stratification in clinical studies.

✅ In October 2025, academic-industry collaborations in Japan integrated wearable sensors into oncology clinical trials to assess physical function and treatment tolerance. Digital biomarkers enabled objective tracking of patient performance status. This improved endpoint consistency across trial sites.

✅ In October 2025, Japanese regulators and research institutions highlighted digital biomarkers as a key enabler for next-generation oncology trials. Emphasis was placed on real-world data integration and continuous monitoring. These efforts aimed to modernize cancer trial execution and outcomes assessment.

Key Players:

=> Koneksa Healthcare, Medidata Solutions, Inc, IBM Watson Health, Philips Healthcare, Syneos Health, Oracle Corporation, Pfizer Inc, NantHealth, Medtronic, Curemetrix among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/digital-biomarkers-in-oncology-clinical-trails-market?sb

Key Segments:

By Product Type

Wearable Devices account for 34% market share, driven by rapid adoption of smartwatches, biosensors, and remote patient monitoring tools for real-time health tracking and chronic disease management.
Mobile Health Apps hold 29%, supported by growing smartphone penetration, personalized health management, telehealth integration, and patient engagement solutions.
Electronic Health Records (EHRs) represent 27%, fueled by healthcare digitization, regulatory mandates, interoperability initiatives, and AI-powered data analytics.
Others account for 10%, including clinical decision support systems, health data platforms, and AI-powered diagnostic dashboards.

By Application

Early Detection & Diagnosis leads with 30% share, driven by AI-powered analytics, predictive modeling, and rising focus on early disease identification to reduce healthcare costs.
Treatment Monitoring accounts for 22%, supported by continuous patient data tracking, remote monitoring technologies, and personalized treatment optimization.
Patient Management holds 20%, fueled by integrated care platforms, chronic disease management tools, and improved care coordination.
Outcome Prediction represents 18%, driven by data-driven clinical insights, real-world evidence analytics, and value-based healthcare adoption.
Market Attractiveness Index accounts for 10%, primarily used by life sciences companies for clinical trial optimization, market forecasting, and strategic planning.

By End User

Pharmaceutical & Biotechnology Companies dominate with 38% share, driven by growing use of digital health analytics in drug development, clinical trials, and real-world evidence generation.
Hospitals and Clinics account for 35%, supported by EHR integration, patient analytics, and AI-enabled decision-support systems.
Research Institutions hold 27%, fueled by data-driven medical research, population health studies, and AI-based disease modeling.

By Region

North America - 36% Share
North America leads due to advanced healthcare IT infrastructure, strong AI adoption, high digital health investments, and presence of major technology and pharmaceutical players.

Europe - 27% Share
Europe follows, supported by healthcare digitization initiatives, data protection frameworks, and AI adoption across hospitals and research institutions.

Asia Pacific - 23% Share
Asia Pacific shows the fastest growth, driven by expanding healthcare access, government digital health programs, rising chronic disease burden, and strong mobile health adoption in China, India, Japan, and Southeast Asia.

Latin America - 8% Share
Latin America's growth is supported by telehealth expansion, healthcare modernization, and increasing adoption of mobile health solutions.

Middle East & Africa - 6% Share
The region benefits from smart healthcare initiatives, investments in digital hospitals, and government-led healthcare transformation programs.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.